Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Calithera Biosciences, Inc.CALA · Entity 113073 | Director · PRESIDENT & CEO | January 23, 2023 | January 25, 2023 |
| Cyteir Therapeutics, Inc.CYT · Entity 92707 | Director | February 03, 2023 | February 07, 2023 |
| GERON CORPGERN · Entity 4989 | Director | May 20, 2026 | May 26, 2026 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director | June 17, 2024 | June 20, 2024 |
| Theravance Biopharma, Inc.TBPH · Entity 5037 | Director | April 27, 2021 | April 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Calithera Biosciences, Inc.
Report date January 23, 2023 · Filed January 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 27,859 |
Reported balance
After 2023-01-23 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-01-23 · Tax withholding · Disposed 526 · Balance 27,859 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 23, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3: Shares are held by the Molineaux Family Trust of which the Reporting Person is a Trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 5,283 |
Reported balance
Holding disclosure · report date 2023-01-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,283 |
| Common StockSEC Table I · non-derivative | Direct | 4,724 |
Reported balance
Holding disclosure · report date 2023-01-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,724 F4: Includes 125 shares acquired on each of December 10, 2021, June 10, 2022 and December 9, 2022, under the Company's 2014 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 23, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
F3: Shares are held by the Molineaux Family Trust of which the Reporting Person is a Trustee.
F4: Includes 125 shares acquired on each of December 10, 2021, June 10, 2022 and December 9, 2022, under the Company's 2014 Employee Stock Purchase Plan.
Cyteir Therapeutics, Inc.
Report date February 03, 2023 · Filed February 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03 | Direct | 14,150 |
Reported balance
After 2023-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-03 · Grant · Acquired 14,150 · Balance 14,150 F1: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date.
GERON CORP
Report date May 20, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2036-05-19 | Direct | 220,000 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 220,000 · Balance 220,000 F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates.
Repare Therapeutics Inc.
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2034-06-16 | Direct | 27,200 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 27,200 · Balance 27,200 F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.
Theravance Biopharma, Inc.
Report date April 27, 2021 · Filed April 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 9,828 |
Reported balance
After 2021-04-27 transaction · row 1
1 source rowRow 1 · 2021-04-27 · Grant · Acquired 9,828 · Balance 9,828 |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.35 · Expires 2031-04-26 | Direct | 6,000 |
Reported balance
After 2021-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-04-27 · Grant · Acquired 6,000 · Balance 6,000 F1: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Family Trust | 41,206 |
Reported balance
Holding disclosure · report date 2021-04-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 41,206 |
Filing footnotes · ownership attribution and instrument terms
F1: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 26, 2026 23:45 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 220,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001553389-26-000002 · form4-05262026_070505.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2036-05-19 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:02 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0000886744-25-000023 · wk-form4_1747947757.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2035-05-20 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:35 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-24-017657 · form4-06202024_040611.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Shares · 27,200 shares Expires 2034-06-16 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| May 09, 2024 Filed May 10, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000950170-24-057798 · ownership.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2034-05-08 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| December 29, 2023 Filed Jan 4, 2024 00:04 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 6,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000546 · doc4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 130,527 F1 · kind: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of the Issuer's Common Stock on December 29, 2023 of $2.11 per share. F1 · price: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of the Issuer's Common Stock on December 29, 2023 of $2.11 per share. Read SEC document |
| September 29, 2023 Filed Oct 2, 2023 23:32 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 6,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-018726 · form4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 124,307 F1 · kind: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of Geron Common Stock on September 29, 2023 of $2.12 per share. F1 · price: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of Geron Common Stock on September 29, 2023 of $2.12 per share. Read SEC document |
| June 30, 2023 Filed Jul 1, 2023 01:19 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 4,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-014272 · form4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 118,116 F1 · kind: Shares issued in lieu of cash payment for annual board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on June 30, 2023 of $3.21 per share. F1 · price: Shares issued in lieu of cash payment for annual board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on June 30, 2023 of $3.21 per share. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:26 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 76,200 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0001209191-23-036313 · doc4.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,200 Underlying: Common Shares · 76,200 shares Expires 2033-06-07 F1 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option shall vest on June 8, 2024, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:34 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001062993-23-012819 · form4.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 01, 2023 Filed May 2, 2023 01:20 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionStock Options (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001062993-23-009883 · form4.xml · derivative · entry 3 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 17, 2023. F1 · derivative.exercise_date: Option was fully vested. Read SEC document |
| May 01, 2023 Filed May 2, 2023 01:20 UTC | GERON CORP GERN · Entity 4989 | SaleCommon Stock | 35,000 | $2.48 | $86,800.00 |
DisclosureSEC source: 0001062993-23-009883 · form4.xml · nonDerivative · entry 2 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 17, 2023. Read SEC document |
| May 01, 2023 Filed May 2, 2023 01:20 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 35,000 | $1.10 | $38,500.00 |
DisclosureSEC source: 0001062993-23-009883 · form4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 17, 2023. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 00:47 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 6,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-008380 · form4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 114,028 F1 · kind: Shares issued in lieu of cash payment for annual board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on March 31, 2023 of $2.17 per share. F1 · price: Shares issued in lieu of cash payment for annual board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on March 31, 2023 of $2.17 per share. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 16:44 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | GrantStock Option (Right to Buy) · Derivative | 14,150 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-23-007547 · doc4.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,150 Underlying: Common Stock · 14,150 shares Expires 2033-02-03 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 16:00 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Tax withholdingCommon Stock | 526 | $0.45 | $234.65 |
DisclosureSEC source: 0000899243-23-002610 · doc4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 27,859 F1 · shares: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 23, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3 · ownership.nature: Shares are held by the Molineaux Family Trust of which the Reporting Person is a Trustee. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:17 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001062993-22-012157 · form4.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-05-09 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 17:01 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | GrantStock Option (Right to Buy) · Derivative | 14,150 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0000899243-22-007650 · doc4.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,150 Underlying: Common Stock · 14,150 shares Expires 2032-02-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on February 22, 2023, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 18:41 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 597,475 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000899243-22-003487 · doc4.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,475 Underlying: Common Stock · 597,475 shares Expires 2032-01-24 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 25, 2022; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| November 10, 2021 Filed Nov 10, 2021 19:34 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | PurchaseCommon Stock | 100,000 | $0.85 | $84,670.00 |
DisclosureSEC source: 0000899243-21-044154 · doc4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 557,188 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8152 to $0.8791, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F2 · ownership.nature: Shares are held by the Molineaux Family Trust of which the Reporting Person is a Trustee. Read SEC document |
| May 11, 2021 Filed May 14, 2021 01:20 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 83,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0000886744-21-000036 · edgar.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2031-05-10 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:13 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $20.35 | $0.00 |
DisclosureSEC source: 0001179110-21-004701 · edgar.xml · derivative · entry 3 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2031-04-26 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:13 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004701 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,828 Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 20:37 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0000899243-21-003050 · doc4.xml · derivative · entry 4 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2031-01-20 F4 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 20, 2021; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 20:37 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003050 · doc4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest as follows: one-fourth (1/4th) of the shares subject to the Restricted Stock Unit will vest each year after January 20, 2021 until the Restricted Stock Units are fully vested. The Restricted Stock Unit shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. F2 · balance_after: Includes 2,500 shares acquired on each of December 10, 2019, June 10, 2020, and December 10, 2020 under the Company's 2014 Employee Stock Purchase Plan. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 22:13 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 83,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000886744-20-000050 · edgar.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 23:56 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $30.14 | $0.00 |
DisclosureSEC source: 0001179110-20-005320 · edgar.xml · derivative · entry 3 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2030-04-27 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 23:56 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 6,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005320 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,635 Read SEC document |
| January 18, 2020 Filed Jan 22, 2020 18:17 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0000899243-20-001696 · doc4.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2030-01-18 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 17, 2020; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | PurchaseCommon Stock | 51,600 | $3.88 | $200,208.00 |
DisclosureSEC source: 0000899243-19-018344 · doc4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 457,188 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.8278 to $3.8938. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · balance_after: Includes 2,500 shares acquired under the Company's 2014 Employee Stock Purchase Plan on December 10, 2018. F3 · ownership.nature: Shares are held by the Molineaux Family Trust, of which the Reporting Person is a Trustee, including 5,000 shares transferred from the Reporting Person and 5,000 shares transferred from the Reporting Person's spouse, to the Molineaux Family Trust on March 27, 2019. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 23:24 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000886744-19-000063 · edgar.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| April 30, 2019 Filed May 2, 2019 22:44 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001179110-19-005477 · edgar.xml · derivative · entry 3 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2029-04-29 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 30, 2019 Filed May 2, 2019 22:44 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 8,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005477 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,385 Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GiftCommon Stock | 12,986 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-003138 · doc4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 395,588 F1 · shares: Represents shares transferred to the Reporting Person's children. The securities owned by the children are not beneficially owned by the Reporting Person. F2 · ownership.nature: Shares are held by the Molineaux Family Trust, of which the Reporting Person is a Trustee Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 16:33 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 390,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0000899243-19-001133 · doc4.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2029-01-09 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 10, 2019; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 00:23 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 13,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-19-000005 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 107,980 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 31, 2018 of $1.00 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 31, 2018 of $1.00 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 31, 2018 of $1.00 per share. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 16:07 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GiftCommon Stock | 6,476 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-029127 · doc4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 408,574 F1 · shares: Represents shares transferred to the Reporting Person's children. The securities owned by the children are not beneficially owned by the Reporting Person. F2 · ownership.nature: Shares are held by the Molineaux Family Trust, of which the Reporting Person is a Trustee, including 44,860 shares transferred from the Reporting Person to the Trust on April 10, 2018. Read SEC document |
| September 28, 2018 Filed Sep 29, 2018 00:03 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 7,457 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-18-000053 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 94,855 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 28, 2018 of $1.76 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 28, 2018 of $1.76 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 28, 2018 of $1.76 per share. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 22:37 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 3,827 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-18-000041 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 87,398 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 29, 2018 of $3.43 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 29, 2018 of $3.43 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 29, 2018 of $3.43 per share. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:48 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000886744-18-000035 · edgar.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-05-14 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates. Read SEC document |
| May 01, 2018 Filed May 3, 2018 22:16 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $24.43 | $0.00 |
DisclosureSEC source: 0001179110-18-006192 · edgar.xml · derivative · entry 3 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 01, 2018 Filed May 3, 2018 22:16 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 8,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006192 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,186 Read SEC document |
| March 29, 2018 Filed Mar 30, 2018 22:06 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 3,088 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-18-000023 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 83,571 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2018 of $4.25 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2018 of $4.25 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2018 of $4.25 per share. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 16:12 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,798 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0000899243-18-006476 · doc4.xml · derivative · entry 5 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 6,798 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 16:12 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 26,992 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0000899243-18-006476 · doc4.xml · derivative · entry 4 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,729 Underlying: Common Stock · 26,992 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 16:12 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionCommon Stock | 26,992 | $2.64 | $71,258.88 |
DisclosureSEC source: 0000899243-18-006476 · doc4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,500 shares acquired under the Company's 2014 Employee Stock Purchase Plan on December 8, 2017. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0000899243-18-001072 · doc4.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-01-10 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 11, 2018; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:21 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 7,292 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-18-000002 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 80,483 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 29, 2017 of $1.80 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 29, 2017 of $1.80 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 29, 2017 of $1.80 per share. Read SEC document |
| December 05, 2017 Filed Dec 6, 2017 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0000899243-17-028063 · doc4.xml · derivative · entry 8 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 6,006 Underlying: Common Stock · 2,700 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| December 05, 2017 Filed Dec 6, 2017 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,502 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000899243-17-028063 · doc4.xml · derivative · entry 7 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 6,502 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| December 05, 2017 Filed Dec 6, 2017 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0000899243-17-028063 · doc4.xml · derivative · entry 6 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,030 Underlying: Common Stock · 5,300 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.